台灣生物精神醫學會 TSBPN Taiwanese Society of Biological Psychiatry and Neuropsychopharmacology The Newsletter for TSBPN Taiwan Newsletter Taiwanese Society of Biological Psychiatry and Neuropsychopharmacology (TSBPN-Bulletin No16, SEP. 2012) http://www.biopsychi.org.tw/communicate/communicate.html 理事長的話 11 454 (8)Bipolar Terence KetterSchizophreniaRené KahnRobert InnisWayne DrevetsMood DisorderJohn KrystalShigenobu KanbaShigeto Yamawaki Kyooseob Ha (CME)8 2 220101 Bipolar disorder (ISBD)chapter3Bipolar disorder Acute manicacute depression maintenance2012211 (WFSBP) (AsCNP) Masa Takeda 1
814(J. of Biological Psychiatry)John KrystalKetamine Glutamateupdate (TSBPN-Bulletin) 15 (1)(2)(2) 20-25% 922Shigenobu Kanba Mood disorderbrain Imaging in SchizophreniaAutismupdate evidence basemood disorder Internet addictionautism Metformin for Treatment of Antipsychotic-Induced Amenorrhea and Weight Gain in Women With First-Episode Schizophrenia: A Double-Blind, Randomized, Placebo-Controlled Study Wu RR, Jin H, Gao K, Twamley EW, Ou JJ, Shao P, Wang J, Guo XF, Davis JM, Chan PK, Zhao JP. Am J Psychiatry. 2012;169(8):813-21 (amenorrhea) metformin 8418-40 1000 mg/day metformin 6BMI prolactinluteinizing hormone (LH)follicle-stimulating hormone (FSH)estradiol testosteronelh/fsh ratio 理事長 766metformin(N=28, 66.7%) (N=2, 4.8%) metforminbmi 0.93 insulin resistance index by 2.04BMI0.85metformin prolactinlh testosteronelh/fsh ratio 246 metformin 2 3
SDS (The Chinese version of the Severity of Dependence Scale as a screening tool for benzodiazepine dependence in Taiwan) (Comorbidities and factors related to discontinuation of pharmacotherapy among outpatients with major depressive disorder) Kaohsiung Journal of Medical Science 2012 April; 28(4): 225-30. Comprehensive Psychiatry 2011;52:370-377 ()228 Mini-International Neuropsychiatric Interview (MINI) - SDS SDSMINIMINI36 SDS SDS(AUC=0.779) 80.5%85.7%7 135(34, 101) DSM-IV-TR(SCID) 53.8% SDS Receiver Operating Characteristic (ROC) analysis SDS : () 4 5
n-3 (Associations between n-3 PUFA concentrations and cognitive function after recovery from late-life depression) (Auditory event-related potential of subjects with suspected pre-psychotic state and firstepisode psychosis) : Frangou SStewart R. Am J Clin Nutr. 2012 Feb;95(2):420-7. n-3 n-3 (Hamilton depression rating scale10) 60(MMSE17) 132(67.8 6.6 ) n-3 EPA(eicosapentaenoic acid)n-3 AA(arachidonic acid)/epa n-3 -linolenic acid (ALA)(immediate recall score) (recurrent)(single episode) n-3ala n-3ala (biomarkers) (late-life depression-high risk group for dementia) pilot studyamerican Journal of Clinical Nutrition hypercortisolemian-3 hippocampusn-3 : Schizophrenia Research 2012 140(1-3):243-9 3 SOPRESStudy on the psychopathological progress of the pre-psychotic state32 (FEP) 30 (UHR) 37(E-BARS) 56 P50N100MMN P50N100 MMN3E-BARSUHRFEP (sensory gating)3p50 (S2/S1)N100 (UHR) P50 N100N100N100N100S2 (pre-attentive) (E-BARS) MMNP50N100 (sensory gating) 6 7
Keynote Speaker Keynote Speaker: Shigenobu Kanba, M. D., Ph.D. Shigenobu Kanba1954(Keio University School of Medicine, Tokyo,)Rochester Mayo Clinic1982-1987 1996(Yamanashi University School of Medicine) 2003(Kyushu University Graduate School of Medicine) Kanba 20014 (World Federation of Societies of Biological Psychiatry) (International Society for Bipolar Disorder) Journal of Psychiatry and Clinical Neuroscience, Molecular Psychiatry (microglia) IFN-gamma microgliail-6nomicroglia Substantial evidence has suggested that neuroinflammatry processes may be involved in the pathogenesis of schizophrenia and/or depression. Pro-inflammatory cytokines and free radicals may thus be involved. Increasing evidence indicates that microglial activation in brain directly by PET studies of schizophrenia and mood disorders. Microglial activation inhibits hippocampal neurogenesis and this impaired hippocampal neurogenesis contributes to the small volumes of hippocampus observed in some psychiatric disorders. Along with these evidences, various types of second-generation antipsychotics (SGA) and some antidepressants inhibit the IFN--induced microglial production of both IL-6 and NO. Anti-inflammatory drugs, and minocyclin, a specific inhibitor of microglial activation, can restore the impaired neurogenesis and were shown to be effective schizophrenia. SGA is known to prevent progress of brain loss in schizophrenia. There is evidence to support some cytokine in peripheral blood may be a good bio-marker for psychiatric disorders. Therefore, further investment into neuroinflammatory pathology and its treatment are essential strategy of psychiatric research. In a proposed symposium, following topics with most update data will be discussed. 1) The role of microglia in the pathology of neuropsychiatric disorders 2) The interaction between neurotrophic system and inflammation in depression: a new direction for diagnosis and treatment 3) The role of peripheral BDNF in pathophysiology of depression and suicide 4) Anti-inflammatory therapy in psychiatric disorders 1. Kato TA, Shinfuku N, Sartorius N, Kanba S.,Are Japan's hikikomori and depression in young people spreading abroad?,lancet,378(9796):1070.,2011.09. 2.Takahiro Kato, Yoshito Mizoguchi, Akira Monji, Hideki Horikawa, Sadayuki Hashioka, Shigenobu Kanba.,Inhibitory effects of aripiprazole on interferon--induced microglial activation via intracellular Ca2+ regulation in Vitro.,Journal of Neurochemistry,106(2): 815-825,2008.07 3. Hirano S, Hirano Y, Maekawa T, Obayashi C, Oribe N, Kuroki T, Kanba S, Onitsuka T,Abnormal neural oscillatory activity to speech sounds in schizophrenia: a MEG study.,j Neuroscience,28(19):4897-903.,2008.05 4. Bian Q, Kato T, Monji A, Hashioka S, Mizoguchi Y, Horikawa H, Kanba S.,The effect of atypical antipsychotics, perospirone, ziprasidone and quetiapine on microglial activation induced by interferon-gamma.,prog Neuropsychopharmacol Biol Psychiatry.,32(1):42-8.,2008.01. 5. Kato T. Monji A. Hashioka S. Kanba S.,Risperidone significantly inhibits interferon-gamma-induced microglial activation in vitro.,schizophrenia Research,92(1-3): 108-115,2007.05. 8 9
10 11
98-101 985298 Prof. Rene KahnIntegrating neuroimaging and genetic approaches in major mental disorders, focusing on schizophrenia and bipolar disorder Prof. Min-Soo Lee Integrated approach of pharmacogenetics on antidepressants 989598 Prof. Qiyong GongImaging the depressed brain: Novel magnetic resonance evidences Prof. Tadafumi KatoNeurobiology of bipolar disorder Prof. A. John RushMeeting everydays challenges in treating major depressive disorder: Pharmacological strategies in achieving remission 994799 蘇東平理事長 Bipolar disorder: experience in Taiwan from Clinical characteristics to treatment Prof. YamawakiNeuroimaging study on mood disorders and eating disorder 9991899 Prof. TA KetterPersonalized, Quantitative, Evidence-Based Treatment for Bipolar Disorders--- Potential to Change Practice Prof. Kyooseob HaStabilizing bipolar disorder: Clinical approach and biological understanding 100430100 梁庚辰教授 Amygdala and Emotional Memory Prof. Masatoshi TakedaIntermediate Phenotypes of Schizophrenia 100827100 Prof. Nobumasa KatoClinical studies of adults with Asperger syndrome ---For exploring the neural basis of autism spectrum disorders (ASD) 鄭雅薇副教授 Empathy in autism: Reduced pain threshold mediates somatosensory response to the pain of others 101519101 簡伯武教授 Modulation of Fear Memory 榮潤國教授 Interface of Sleep Disorders and Psychiatry 101922101 曾文毅教授 Altered brain structure and function in schizophrenia Prof. Shigenobu KanbaNeuroinflammatory hypothesis of schizophrenia 蘇東平理事長 New thoughts of strategic plan for mood disorders: Where do we go from here? 98613-14 邱震寰醫師 MRI 周元華醫師 林永煬教授 (MEG) 謝明憲教授 9810172009 劉英杰醫師 蔡世仁醫師 陳嘉祥教授 () 林明薇副教授 () 99116(II) Prof. Professor Gin S. MalhiThe Pharmacotherapy of Bipolar Disorder: New Paradigms and New Molecules 陳嘉祥教授 () 林明薇副教授 () 99515(II) Robert B. Innis, MD, PhDPositron Emission Tomography: Tool to Study Pathophysiology and to Facilitate Drug Development Victor Pike, PhDRadioligand development and use mglur5 杜培基醫師 Functional connectivity of schizophrenia 100326 楊延光教授 高淑芬教授 白雅美副教授 顏正芳教授 林明薇副教授 蔡世仁教授 100528 洪賢明 王淑真博士 Learning versus evidence setting Methodology for learning trials Methodology for evidence-setting trialsstatistical methods and considerationsroles of integrated analyses Preview of recent advances and emerging issues of clinical trial methodology 100625 李怡慧醫師 Theta burst stimulation primes the lesional hemisphere for motor recovery in subacute stroke patients 李正達醫師 Dissociable Mechanisms of Repetitive Transcranial Magnetic Stimulation in Treating Depression and Medically Unexplained Pain 力博宏醫師 Effect of Repeated Transcranial Magnetic Stimulation (rtms) on Central Auditory Pathway in Patients with Tinnitus 黃英儒醫師 Neuroplasticity and Its Modulation in Movement Disorders 阮啟宏教授 Using TMS and tdcs to probe the role of presupplementary motor area in the inhibitory control 98613-14 陶明醫師 胡建醫師 張瑛醫師 : 99814 劉義蘭教授 The Treatment of Depression 朱紫青教授 99109 10093 1001217 101814Prof. John H. Krystal Glutamatergic Treatment Strategies for Schizophrenia and Depression: A Translational Neuroscience Perspective 12 13
14 15
雜 誌 印刷品 此刊物為醫療教育刊物, 歡迎來函免費索取, 並請傳閱 謝謝! 1. 1 2. Metformin for Treatment of Antipsychotic-Induced Amenorrhea and Weight Gain in Women With First-Episode Schizophrenia: A Double-Blind, Randomized, Placebo-Controlled Study / 3 3. 目錄 SDS/ 4 / 5 n-3/ 6 / 7 4. Keynote Speaker 8 5. WFSBP Congress 2013 11 6. 98-101 12 201 /(02)2871-4424 E-mail: psygrace1@gmail.com http://www.biopsychi.org.tw/ 19742461 16